Analysis of the risks associated with calcium channel blockade: Implications for the obstetrician-gynecologist

Obstetrical and Gynecological Survey

Volumn 52, Issue 3, 1997, Pages 198-201

  Davis, Wesley B ^a   Wells, Steven R ^a   Kuller, Jeffrey A ^a   Thorp Jr , John M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAGNESIUM SULFATE; NIFEDIPINE; NIMODIPINE; VERAPAMIL;

ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; BRAIN HEMORRHAGE; CANCER RISK; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PREECLAMPSIA; PREGNANCY; RAT; REVIEW; RISK ASSESSMENT; SEIZURE; TOCOLYSIS;

CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASES; HUMANS; MAGNESIUM SULFATE; NEOPLASMS; NIFEDIPINE; PREGNANCY; PREGNANCY COMPLICATIONS; TOCOLYTIC AGENTS;

EID: 0031027601     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199703000-00023     Document Type: Review

References (18)

1. Childress CH, Katz VL. Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol 1994;83:616-624.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
3. Pahor JM, Guralnik ME, Salive ME et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertension 1996;9:695-699.
4. Pahor M, Guralnik JM, Furberg CD et al. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-1065.
5. Thorp JM, Spielman FJ, Valea FA et al. Nifedipine enhances the cardiac toxicity of magnesium sulfate in the isolated perfused Sprague-Dawley rat heart. Am J Obstet Gynecol 1990; 163:655-656.
6. Kurtzman JL, Thorp JM, Mueller RA et al. Do nifedipine and verapamil potentiate the cardiac toxicity of magnesium sulfate? Am J Perinatol 1993;6:450-452.
7. Waisman GD, Mayorga LM, Camera MI et al. Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia. Am J Obstet Gynecol 1988;159:308-309.
8. Lichtlen PR, Hugenholtz PG, Rafflenbeul W et al. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy). Cardiovasc Drug Ther 1990;4:1047-1068.
9. Opie LH, Messerli FH. Nifedipine and mortality: Grave defects in the dossier. Circulation 1995;92:1068-1073
10. Muller JE, Morrison J, Stone PH et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind placebo-controlled comparison. Circulation 1984;69:740-747.
11. Cornoni-Huntley J, Ostfeld AM, Taylor JO. Established populations for epidemiologic studies of the elderly: Study design and methodology. Aging Clin Exp Res 1993;5:27-37.
12. Pahor M, Guralnik JM, Ferrucci L et al. Calcium channel blockage and incidence of cancer in aged populations. Lancet 1996;348:493-497.
13. Daling JR. Calcium channel blockers and cancer: Is an association biologically plausible? Am J Hypertens 1996;9:713-714.
14. Wagenknhect LE, Furgerg CD, Hammon JW et al. Surgical bleeding: Unexpected effect of a calcium antagonist. Br Med J 1995;310:776-777.
15. Gore JM, Sloan M, Price TR. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 1991;83:448-459.
16. Kario K, lmiya M, Ohat Y et al. Gastrointestinal bleeding induced by amlodipine. J Hum Hypertens 1995;9:206-207.
17. Scardo JA, Vermillion ST, Hogg BB et al. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996;175:336-340.
18. Davis BR, Cutler JA, Gordon JD et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.